Bioavailability, Pharmacokinetics, and Analgesic Activity of Ketamine in Humans
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The pharmacokinetics of ketamine in analgesic doses after intravenous, intramuscular, and oral administration was investigated in healthy volunteers. Plasma ketamine concentration-time curves were fitted by a two-compartment open model with a terminal half-life of 186 min. Absorption after intramuscular injection was rapid and the bioavailability was 93%. However, only 17% of an oral dose was absorbed because of extensive first-pass metabolism. Simultaneous measurements of the elevation of pain threshold in an ischemic exercise test showed a marked effect for 15-60 min after intramuscular injection, but little or no effect after the oral solution. Pain threshold elevation occurred at plasma ketamine concentrations above 160 ng/ml.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Regarding elimination of ketamine and its metabolites, the elimination half-life is between two to four hours, varying slightly with the route of administration”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Clements et al., 1982
Citations
Cites
A Simplex Method for Function Minimization
Nelder, J. A., & Mead, R. (1965) · The Computer Journal · doi:10.1093/comjnl/7.4.308 · Cited by 28,905
TESTING FOR SERIAL CORRELATION IN LEAST SQUARES REGRESSION. II
DURBIN, J., & WATSON, G. S. (1951) · Biometrika · doi:10.1093/biomet/38.1-2.159 · Cited by 3,619
Drugs and the Pharmaceutical Sciences
(2010) · Drugs and the pharmaceutical sciences · doi:10.1201/ihcdruphasci · Cited by 586
New Method for Calculating the Intrinsic Absorption Rate of Drugs
Loo, J. C. K., & Riegelman, S. (1968) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600570602 · Cited by 466
PHARMACOKINETICS AND ANALGESIC EFFECTS OF I.M. AND ORAL KETAMINE
GRANT, I. S., NIMMO, W. S., & CLEMENTS, J. A. (1981) · British Journal of Anaesthesia · doi:10.1093/bja/53.8.805 · Cited by 355
Self-citationPHARMACOKINETICS AND ANALGESIC EFFECT OF KETAMINE IN MAN
CLEMENTS, J. A., & NIMMO, W. S. (1981) · British Journal of Anaesthesia · doi:10.1093/bja/53.1.27 · Cited by 322
Self-citationKETAMINE INFUSIONS: PHARMACOKINETICS AND CLINICAL EFFECTS
IDVALL, J., AHLGREN, I., ARONSEN, K. F., & STENBERG, P. (1979) · British Journal of Anaesthesia · doi:10.1093/bja/51.12.1167 · Cited by 306
Influence of Route of Administration on Drug Availability
Rowland, M. (1972) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600610111 · Cited by 264
Pedersen, P. V. (1977) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061732 · Cited by 219
Ottaway, J. H. (1973) · Biochemical Journal · doi:10.1042/bj1340729 · Cited by 101
Research works printed but not linked: 9
- Wieber, 1975, Anaesthetist, 24, 260
- Clausen, 1975, Med. J., 49, 1437
- Harrison, 1943, Proc. Assoc. Res. Nerv. Ment. Dis., 23, 154
- Walle, 1970, Acta Pharm. Suec., 7, 389
- Durbin, 1950, Biometrika, 37, 409
- Gibaldi, 1979, Vol. 1, 232
- Rowland, 1972, ibid, 61, 70
- Gibaldi, 1971, ibid., 60, 624
- Pang, 1978, ibid., 67, 703
Cited by
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression
Yang, Y., Cui, Y., Sang, K., Dong, Y., Ni, Z., Ma, S., & Hu, H. (2018) · Nature · doi:10.1038/nature25509 · Cited by 1,036
Ketamine Pharmacology: An Update ( Pharmacodynamics and Molecular Aspects, Recent Findings )
Mion, G., & Villevieille, T. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12099 · Cited by 711
“The ketamine analgesic effect persists for steady-state plasma concentrations superior to 100–160 ng/ml [49] (about 0.”
BackgroundKetamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy
Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., & Saari, T. I. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0383-6 · Cited by 672
“Following an intramuscular dose of 2–4 mg/kg, ketamine is rapidly absorbed and bioavailability is approximately 93 % [10, 11].”
Schwenk, E. S., Viscusi, E. R., Buvanendran, A., Hurley, R. W., Wasan, A. D., Narouze, S., Bhatia, A., Davis, F. N., Hooten, W. M., & Cohen, S. P. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000806 · Cited by 584
“Ketamine produces analgesia at plasma concentrations of 100 to 200 ng/mL, which represent a small fraction of plasma concentrations after general anesthesia doses (9000–25,000 ng/mL).(29,30) The common subanesthetic dose of ketamine used in clinical practice is intravenous (IV) 0.”
Signaling pathways underlying the rapid antidepressant actions of ketamine
Duman, R. S., Li, N., Liu, R.-J., Duric, V., & Aghajanian, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.044 · Cited by 537
“This is presumably because of the rapid metabolism of ketamine (half-life is 180min in humans; Clements et al.,1982).”
Ketamine – More mechanisms of action than just NMDA blockade
Sleigh, J., Harvey, M., Voss, L., & Denny, B. (2014) · Trends in Anaesthesia and Critical Care · doi:10.1016/j.tacc.2014.03.002 · Cited by 434
Ketamine: 50 Years of Modulating the Mind
Li, L., & Vlisides, P. E. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00612 · Cited by 385
“However, in certain settings such as emergencies or with uncooperative patients, IM ketamine is commonly used and has only a slightly lower bioavailability of 93% (Clements et al., 1982).”
BackgroundMcCartney, C. J. L., Sinha, A., & Katz, J. (2004) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000108501.57073.38 · Cited by 358
Ketamine in Chronic Pain Management: An Evidence-Based Review
Hocking, G., & Cousins, M. J. (2003) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000086618.28845.9b · Cited by 349
“(47) found consistent increases of pain thresholds for plasma concentrations of racemic ketamine more than 160 ng/mL (0.”
BackgroundEide, P. K., Stubhaug, A., Øye, I., & Breivik, H. (1995) · Pain · doi:10.1016/0304-3959(94)00182-e · Cited by 258
Kalsi, S. S., Wood, D. M., & Dargan, P. I. (2011) · Emerging Health Threats Journal · doi:10.3402/ehtj.v4i0.7107 · Cited by 234
“Bioavailability (%) 100% 93% (9) 17% (9) 25% (10) 25 50% (10)”
Ketamine and depression: a narrative review
Corriger, A., & Pickering, G. (2019) · Drug Design, Development and Therapy · doi:10.2147/dddt.s221437 · Cited by 211
“Ketamine pharmacokinetics – pharmacodynamics Concerning ketamine kinetics, once absorbed it is rapidly distributed in the brain and highly perfused tissues, the distribution half-life is short in the range of 2–4 mins, and the elimination half-life 2–4 hrs.(66,69) Ketamine’s pharmacokinetics could partly explain ketam…”
BackgroundSustained antidepressant effect of ketamine through NMDAR trapping in the LHb
Ma, S., Chen, M., Jiang, Y., Xiang, X., Wang, S., Wu, Z., Li, S., Cui, Y., Wang, J., Zhu, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06624-1 · Cited by 204
“Minor point.”
Willert, R. P., Woolf, C. J., Hobson, A. R., Delaney, C., Thompson, D. G., & Aziz, Q. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.047 · Cited by 202
Naughton, M., Clarke, G., O′Leary, O. F., Cryan, J. F., & Dinan, T. G. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.11.014 · Cited by 190
“Its use had been associated with dissociative reactions on emerging from anaesthesia; however, it remains a desirable anaesthetic because of its short half-life (180 min) and the lack of respiratory depression (Clemens et al. 1982).”
BackgroundPain care for patients with epidermolysis bullosa: best care practice guidelines
Goldschneider, K. R., Good, J., Harrop, E., Liossi, C., Lynch-Jordan, A., Martinez, A. E., Maxwell, L. G., & Stanko-Lopp, D. (2014) · BMC Medicine · doi:10.1186/s12916-014-0178-2 · Cited by 185
“Ketamine is more rapidly effective and can be given orally [84-86,175] or used subcutaneously (see below).”
Finch, P. M., Knudsen, L., & Drummond, P. D. (2009) · Pain · doi:10.1016/j.pain.2009.05.017 · Cited by 178
“The plasma levels of ketamine above 150 lg/l have previously been shown to cause pain threshold elevation [9,92].”
BackgroundMechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Use of oral ketamine in chronic pain management: A review
Blonk, M. I., Koder, B. G., van den Bemt, P. M. L. A., & Huygen, F. J. P. M. (2010) · European Journal of Pain · doi:10.1016/j.ejpain.2009.09.005 · Cited by 168
“After oral intake, the main metabolite norketamine reaches much higher plasma levels due to extensive first-pass metabolism (Grant et al., 1981; Clements et al., 1982).”
BackgroundInfluentialIrwin, S. A., Iglewicz, A., Nelesen, R. A., Lo, J. Y., Carr, C. H., Romero, S. D., & Lloyd, L. S. (2013) · Journal of Palliative Medicine · doi:10.1089/jpm.2012.0617 · Cited by 167
The Use of a Ketamine-Propofol Combination During Monitored Anesthesia Care
Badrinath, S., Avramov, M. N., Shadrick, M., Witt, T. R., & Ivankovich, A. D. (2000) · Anesthesia & Analgesia · doi:10.1097/00000539-200004000-00016 · Cited by 164
Ketamine for the treatment of addiction: evidence and potential mechanisms
Ivan Ezquerra-Romano, I., Lawn, W., Krupitsky, E., & Morgan, C. J. A. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.017 · Cited by 163
“Ketamine has a relatively short half-life of 1e3 h, so its subjective effects cease quickly after administration stops (Clements et al., 1982).”
Niciu, M. J., Henter, I. D., Luckenbaugh, D. A., Zarate, C. A., & Charney, D. S. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135950 · Cited by 161
“Ketamine’s plasma half-life is 1 to 3 h (17), and norketamine’s plasma half-life is 12 h.”
BackgroundPharmacologically Active Drug Metabolites: Impact on Drug Discovery and Pharmacotherapy
Obach, R. S. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005439 · Cited by 159
Zahn, P. K., & Brennan, T. J. (1998) · Anesthesiology · doi:10.1097/00000542-199801000-00022 · Cited by 160
From “Special K” to “Special M”: The Evolution of the Recreational Use of Ketamine and Methoxetamine
Corazza, O., Assi, S., & Schifano, F. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12063 · Cited by 146
“The pharmacokinetics of KET in analgesic doses after intravenous (IV), intramuscular (IM), and oral administration was investigated in healthy volunteers [22].”
BackgroundLara, D. R., Bisol, L. W., & Munari, L. R. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000485 · Cited by 138
“…oral administration undergoes rapid first pass metabolism, resulting in only 17% bioavailability and high conversion to the metabolite norketamine (Clements et al., 1982), but there are three case reports of successful treatment with 0.5mg/kg oral ketamine in patients receiving hospice care…”
BackgroundRole of Ketamine in Acute Postoperative Pain Management: A Narrative Review
Radvansky, B. M., Shah, K., Parikh, A., Sifonios, A. N., Le, V., & Eloy, J. D. (2015) · BioMed Research International · doi:10.1155/2015/749837 · Cited by 149
Rogers, R., Wise, R. G., Painter, D. J., Longe, S. E., & Tracey, I. (2004) · Anesthesiology · doi:10.1097/00000542-200402000-00018 · Cited by 132
Perioperative Ketamine for Analgesia in Spine Surgery
Pendi, A., Field, R., Farhan, S.-D. B., Eichler, M. C., & Bederman, S. S. (2017) · Spine · doi:10.1097/brs.0000000000002318 · Cited by 130
“For example, ketamine was administered solely intraoperatively in several trials; given that the half-life of ketamine is approximately 186 minutes, analgesic effects may dissipate soon after intraoperative infusion is terminated.(26) Another possible explanation may be dosing: Pestieau et al.”
BackgroundWilson, J. A., Nimmo, A. F., Fleetwood-Walker, S. M., & Colvin, L. A. (2008) · Pain · doi:10.1016/j.pain.2007.05.011 · Cited by 124
“Specific effects on sensory processing were also detected, with a selective decrease in mechanical sensitivity on the stump that outlasted the expected pharmacological action of ketamine (Clements et al., 1982), similar to that seen in established phantom and stump pain (Nikolajsen et al.”
BackgroundTherapeutic infusions of ketamine: do the psychoactive effects matter?
Dakwar, E., Anerella, C., Hart, C. L., Levin, F. R., Mathew, S. J., & Nunes, E. V. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.12.019 · Cited by 123
“Thus, the lack of observed effect in the previous study might be attributed to the reduced bioavailability of ketamine by the IM route compared to IV (Clements et al., 1982) as well as the low doses administered (0.”
ResultInfluentialKetamine enantiomers in the rapid and sustained antidepressant effects
Muller, J., Pentyala, S., Dilger, J., & Pentyala, S. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316631267 · Cited by 122
“Ketamine is a desirable anesthetic because of its short half-life (180 min) and the lack of respiratory depression [Clemens et al. 1982].”
BackgroundQuibell, R., Prommer, E., Mihalyo, M., Twycross, R., & Wilcock, A. (2011) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2011.01.001 · Cited by 143
Swainson, J., McGirr, A., Blier, P., Brietzke, E., Richard-Devantoy, S., Ravindran, N., Blier, J., Beaulieu, S., Frey, B. N., Kennedy, S. H., et al. (2021) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720970860 · Cited by 110
An audit of perioperative management of autistic children
Van Der Walt, J. H., & Moran, C. (2001) · Pediatric Anesthesia · doi:10.1046/j.1460-9592.2001.00688.x · Cited by 109
Fanta, S., Kinnunen, M., Backman, J. T., & Kalso, E. A. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1826-y · Cited by 122
Lateral Habenular Burst Firing as a Target of the Rapid Antidepressant Effects of Ketamine
Cui, Y., Hu, S., & Hu, H. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.12.002 · Cited by 106
“Apart from its rapid action, ketamine also has a fast metabolic turnover rate, with a half-life of 3 h in humans [23].”
Hijazi, Y., Bodonian, C., Bolon, M., Salord, F., & Boulieu, R. (2003) · British Journal of Anaesthesia · doi:10.1093/bja/aeg028 · Cited by 115
Ketamine for chronic non-cancer pain
Bell, R. F. (2009) · Pain · doi:10.1016/j.pain.2008.12.003 · Cited by 104
“5 mg/kg is not satisfactory for producing analgesia [11].”
BackgroundJafarinia, M., Afarideh, M., Tafakhori, A., Arbabi, M., Ghajar, A., Noorbala, A. A., Saravi, M. A., Agah, E., & Akhondzadeh, S. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.05.076 · Cited by 104
Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine
Shimoyama, M., Shimoyama, N., Gorman, L. A., Elliott, K. J., & Inturrisi, C. E. (1999) · Pain · doi:10.1016/s0304-3959(98)00269-3 · Cited by 95
Sherlock, K., Wolff, K., Hay, A. W. M., & Conner, M. T. (1999) · Emergency Medicine Journal · doi:10.1136/emj.16.3.194 · Cited by 94
Development of a Sublingual/Oral Formulation of Ketamine for Use in Neuropathic Pain
Chong, C., Schug, S. A., Page‐Sharp, M., Jenkins, B., & Ilett, K. F. (2009) · Clinical Drug Investigation · doi:10.2165/00044011-200929050-00004 · Cited by 93
Arabzadeh, S., Hakkikazazi, E., Shahmansouri, N., Tafakhori, A., Ghajar, A., Jafarinia, M., & Akhondzadeh, S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.056 · Cited by 89
Erhan, E., Uğur, G., Alper, I., Gunusen, I., & Ozyar, B. (2005) · European Journal of Anaesthesiology · doi:10.1017/s0265021503000073 · Cited by 87
Pre-hospital use of ketamine for analgesia and procedural sedation
Bredmose, P. P., Lockey, D., Grier, G., Watts, B., & Davies, G. (2008) · Emergency Medicine Journal · doi:10.1136/emj.2007.052753 · Cited by 88
Preparing New World Monkeys for Laboratory Research
Tardif, S., Bales, K., Williams, L., Moeller, E. L., Abbott, D., Schultz-Darken, N., Mendoza, S., Mason, W., Bourgeois, S., & Ruiz, J. (2006) · ILAR Journal · doi:10.1093/ilar.47.4.307 · Cited by 83
“When used with xylazine, it is possible to obtain good muscular relaxation (Bennett 2003; Butler et al. 1995; Clements et al. 1982; Ochsner 1977).”
Prediction of difficult tracheal intubation
Iohom, G., Ronayne, M., & Cunningham, A. J. (2005) · European Journal of Anaesthesiology · doi:10.1017/s0265021503000061 · Cited by 82
Ketamine for analgosedation in critically ill patients
Erstad, B. L., & Patanwala, A. E. (2016) · Journal of Critical Care · doi:10.1016/j.jcrc.2016.05.016 · Cited by 86
Oral ketamine for the treatment of pain and treatment-resistant depression
Schoevers, R. A., Chaves, T. V., Balukova, S. M., Rot, M. A. H., & Kortekaas, R. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.165498 · Cited by 81
Stringer, R. A., Strain-Damerell, C. M., Nicklin, P. L., & Houston, J. B. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.024810 · Cited by 83
Gilling, K. E., Jatzke, C., Hechenberger, M., & Parsons, C. G. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.01.012 · Cited by 82
“Physiologically, NMDA receptors are transiently activated by mM concentrations of glutamate (Clements et al., 1992) following strong depolarization of the postsynaptic membrane which rapidly relieves their voltagedependent blockade by Mg2þ (Nowak et al.”
Topical Ketamine in the Treatment of Mucositis Pain
Slatkin, N. E., & Rhiner, M. I. (2003) · Pain Medicine · doi:10.1046/j.1526-4637.2003.03032.x · Cited by 74
A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect
Lee, Y., Syeda, K., Maruschak, N. A., Cha, D. S., Mansur, R. B., Wium-Andersen, I. K., Woldeyohannes, H. O., Rosenblat, J. D., & McIntyre, R. S. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000441 · Cited by 74
“Ketamine has been demonstrated to act as a rapid-onset, NMDA receptor antagonist.(9,10) Ketamine is commonly used for anesthetic purposes in surgical settings at doses of 1 to 2 mg/kg; its elimination half-life is 186 minutes.”
BackgroundXu, Y. Y., Li, Y., Huang, X., Chen, D., She, B.-Z., & Ma, D. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4334-8 · Cited by 80
Analgesia from morphine and ketamine
Owen, H., REEKIE, R. M., CLEMENTS, J. A., Watson, R. D., & Nimmo, W. S. (1987) · Anaesthesia · doi:10.1111/j.1365-2044.1987.tb05167.x · Cited by 74
Self-citationEffects of norketamine enantiomers in rodent models of persistent pain
HOLTMANJR, J., Crooks, P. A., JOHNSONHARDY, J., HOJOMAT, M., Kleven, M. S., & Wala, E. P. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.05.011 · Cited by 80
“Low oral bioavailability of ketamine was also thought to be due to the first-pass effect, and to the formation of norketamine (Grant et al.,1981; Clements et al.,1982).”
Yamamoto, S., Ohba, H., Nishiyama, S., Harada, N., Kakiuchi, T., Tsukada, H., & Domino, E. F. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.176 · Cited by 76
“This is surprising because of an approximate 3-h half-life of ketamine in plasma (Clements et al, 1982) and its absence in brain in 24 h.”
The clinical toxicology of ketamine
Schep, L. J., Slaughter, R. J., Watts, M., Mackenzie, E., & Gee, P. (2023) · Clinical Toxicology · doi:10.1080/15563650.2023.2212125 · Cited by 88
“Bioavailability (%) Intramuscular 93 [48,49] Oral 16–20 [48–50] Sublingual 32 [50] Intranasal 8–50 [3,51] Rectal 25–30 [50,51] Time to peak plasma concentrations (min) Intramuscular 5–30 [48,49] Oral 20–120 [3,48–50,52] Sublingual 40 [50] Intranasal 22 [50] Rectal 30–60 [53,54] Epidural 77 [55]”
BackgroundKim, C.-Y., Lee, H., Han, S., Heo, J., Kwon, M.-S., Ha, C., & Han, S. (2005) · Journal of Medical Primatology · doi:10.1111/j.1600-0684.2005.00097.x · Cited by 72
Katz, J., Schmid, R., Snijdelaar, D. G., Coderre, T. J., McCartney, C. J. L., & Wowk, A. (2004) · Pain · doi:10.1016/j.pain.2004.05.011 · Cited by 72
Topical and Peripheral Ketamine as an Analgesic
Sawynok, J. (2014) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000000246 · Cited by 84
Niezgoda, J., & Bansal, V. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06612-9.00002-x · Cited by 72
Anesthetics inhibit high‐affinity states of dopamine D2 and other G‐linked receptors
Seeman, P., & Kapur, S. (2003) · Synapse · doi:10.1002/syn.10221 · Cited by 68
“The alleviation of pain in humans occurs above 0.67 M ketamine in plasma (Clements et al., 1982), with psychotic effects occurring between 0.5 and 1 M ketamine (Bowdle et al., 1998).”
BackgroundInfluentialHERD, D., & ANDERSON, B. J. (2007) · Pediatric Anesthesia · doi:10.1111/j.1460-9592.2006.02145.x · Cited by 68
Persson, J., Hasselström, J., Wiklund, B., Heller, A. R., Svensson, J. O., & Gustafsson, L. L. (1998) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.1998.tb05317.x · Cited by 67
“, who found consistent elevations of pain thresholds for plasma concentrations of racemic ketamine greater than 160 ng/ml in experimental ischemic pain (26).”
BackgroundOn the safety and benefits of repeated intravenous injections of ketamine for depression.
Blier, P., Zigman, D., & Blier, J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.039 · Cited by 64
Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence
Subramanian, S., Haroutounian, S., Palanca, B. J. A., & Lenze, E. J. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120152 · Cited by 76
Woelfer, M., Li, M., Colic, L., Liebe, T., Di, X., Biswal, B., Murrough, J., Lessmann, V., Brigadski, T., & Walter, M. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1679391 · Cited by 64
Pai, A., & Heining, M. P. D. (2007) · Continuing Education in Anaesthesia Critical Care & Pain · doi:10.1093/bjaceaccp/mkm008 · Cited by 64
Highland, J. N., Morris, P. J., Zanos, P., Lovett, J., Ghosh, S., Wang, A. Q., Zarate, C. A., Thomas, C. J., Moaddel, R., & Gould, T. D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118812095 · Cited by 62
“Moreover, due to its poor oral bioavailability (BA; approximately 17–24% in humans) (Chong et al., 2009; Clements et al., 1982; Grant et al., 1981; Yanagihara et al., 2003), ketamine is most frequently administered via intravenous (i.v.) infusion, making outpatient treatment challenging.”
Drug Pharmacokinetics Determined by Real‐Time Analysis of Mouse Breath
Li, X., Sinues, P., Dallmann, R., Bregy, L., Hollmén, M., Proulx, S. T., Brown, S. A., Detmar, M. J., Kohler, M., & Zenobi, R. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201503312 · Cited by 69
Reuter, D. A., Felbinger, T. W., Schmidt, C., Mörstedt, K., Kilger, E., Lamm, P., & Goetz, A. E. (2003) · European Journal of Anaesthesiology · doi:10.1017/s0265021503000036 · Cited by 69
Hull, T. D., Malgaroli, M., Gazzaley, A., Akiki, T. J., Madan, A., Vando, L., Arden, K., Swain, J., Klotz, M., & Paleos, C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.07.004 · Cited by 58
“The initial adjustment assumed a 20 % bioavailability based on sublingual bioavailability studies (Chong et al., 2009; Clements et al., 1982; Yanagihara et al., 2003) and the observed effects of Mindbloom's administration protocol described in this section below that involved spitting instead of…”
Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults.
Lofwall, M. R., Griffiths, R. R., & Mintzer, M. Z. (2006) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.14.4.439 · Cited by 58
Peltoniemi, M. A., Saari, T. I., Hagelberg, N. M., Laine, K., Kurkinen, K. J., Neuvonen, P. J., & Olkkola, K. T. (2012) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2012.00908.x · Cited by 56
Kamp, J., Olofsen, E., Henthorn, T. K., van Velzen, M., Niesters, M., Dahan, A., & for the Ketamine Pharmacokinetic Study Group (2020) · Anesthesiology · doi:10.1097/aln.0000000000003577 · Cited by 58
The rapid anti-suicidal ideation effect of ketamine: A systematic review
Hochschild, A., Grunebaum, M. F., & Mann, J. J. (2021) · Preventive Medicine · doi:10.1016/j.ypmed.2021.106524 · Cited by 55
Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S‐ketamine
Hagelberg, N. M., Peltoniemi, M. A., Saari, T. I., Kurkinen, K. J., Laine, K., Neuvonen, P. J., & Olkkola, K. T. (2010) · European Journal of Pain · doi:10.1016/j.ejpain.2009.10.003 · Cited by 55
“After oral administration, peak plasma concentrations (Cmax) are reached in approximately 30 min (Grant et al., 1981; Clements et al., 1982; Yanagihara et al., 2003).”
BackgroundExposure to Oral S-ketamine Is Unaffected by Itraconazole but Greatly Increased by Ticlopidine
Peltoniemi, M. A., Saari, T. I., Hagelberg, N. M., Reponen, P., Turpeinen, M., Laine, K., Neuvonen, P. J., & Olkkola, K. T. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.140 · Cited by 54
Criminal Poisoning: Drug-Facilitated Sexual Assault
Bechtel, L. K., & Holstege, C. P. (2007) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2007.02.008 · Cited by 62
Bergadano, A., Andersen, O. K., Arendt‐Nielsen, L., Theurillat, R., Thormann, W., & Spadavecchia, C. (2008) · The Veterinary Journal · doi:10.1016/j.tvjl.2008.06.003 · Cited by 53
Niciu, M. J., Grunschel, B. D., Corlett, P. R., Pittenger, C., & Bloch, M. H. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113486718 · Cited by 52
The neurophysiology of ketamine: an integrative review
McMillan, R. L., & Muthukumaraswamy, S. D. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0090 · Cited by 54
Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression
Rivas-Grajales, A. M., Salas, R., Robinson, M. E., Qi, K., Murrough, J. W., & Mathew, S. J. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa089 · Cited by 51
The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence
Ragnhildstveit, A., Roscoe, J., Bass, L. C., Averill, C. L., Abdallah, C. G., & Averill, L. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231154125 · Cited by 56
Andrade, C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15f10026 · Cited by 49
The Anaesthetic Management of Autistic Children
Rainey, L., & WALT, J. H. V. D. (1998) · Anaesthesia and Intensive Care · doi:10.1177/0310057x9802600615 · Cited by 49
Corkery, J., Hung, W.-C., Claridge, H., Goodair, C., Copeland, C. S., & Schifano, F. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211021588 · Cited by 63
“(Clements et al., 1982; Malinovsky et al., 1996).”
Breeksema, J. J., Niemeijer, A. R., Kuin, B., Veraart, J. K. E., Kamphuis, J., Schimmel, N., van den Brink, W., Vermetten, E. H. G. J. M., & Schoevers, R. A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.948115 · Cited by 53
Multistage drug effects of ketamine in the treatment of major depression
Walter, M., Li, S., & Demenescu, L. R. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0535-3 · Cited by 50
Oral ketamine for pediatric outpatient dental surgery sedation.
Alfonzo-Echeverri, E. C., Berg, J., Wild, T. W., & Glass, N. (1993) · PubMed · Cited by 47
Postoperative sore throat and ketamine gargle
Chan, L. Y. S., Lee, M. L., & Lo, Y. L. (2010) · British Journal of Anaesthesia · doi:10.1093/bja/aeq152 · Cited by 47
Brimacombe, J. R., & KELLER, C. (2005) · European Journal of Anaesthesiology · doi:10.1017/s0265021503000127 · Cited by 46
Balanced Anesthesia and Constant-Rate Infusions in Horses
Valverde, A. (2012) · Veterinary Clinics of North America Equine Practice · doi:10.1016/j.cveq.2012.11.004 · Cited by 45
Pałucha-Poniewiera, A., Szewczyk, B., & Pilc, A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.03.001 · Cited by 48
“Because the metabolism of ketamine is rapid (the half-life in humans is 180 min; Clements et al., 1982) and the antidepressant effects last up to 7 days (Zarate et al.”
BackgroundSwainson, J., Klassen, L. J., Brennan, S., Chokka, P. R., Katzman, M. A., Tanguay, R. L., & Khullar, A. (2022) · CNS Drugs · doi:10.1007/s40263-022-00897-2 · Cited by 54
“Given differences in kinetics, dosing, and bioavailability of PO (17%) [36], SL (29%) [37], and IN (50%) [38] ketamine formulations, it is unclear whether the safety and side effect profiles are entirely consistent across various formulations.”
BackgroundSt John’s wort greatly decreases the plasma concentrations of oral S‐ketamine
Peltoniemi, M. A., Saari, T. I., Hagelberg, N. M., Laine, K., Neuvonen, P. J., & Olkkola, K. T. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.00954.x · Cited by 44
Metadata
- Authors
- Clements, J. A., Nimmo, W. S., & Grant, I. S.
- Affiliations
- Heriot-Watt University (GB)
- Western Infirmary (GB)
- Corresponding author
- Clements, J.A.
- ORCID
- Grant, I.S.
- Venue
- Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 1982-05
- Volume
- 71
- Issue
- 5
- Pages
- 539-542
- ISSN
- 0022-3549 (ISSN-L)
- OpenAlex
- W2094496261
- Cited by
- 420
- References
- 20
- Citations by year
- 2026: 20 · 2025: 25 · 2024: 17 · 2023: 20 · 2022: 34 · 2021: 17 · 2020: 50 · 2019: 11 · 2018: 20 · 2017: 13 · 2016: 20 · 2015: 16 · 2014: 21 · 2013: 16 · 2012: 10
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Pharmaceutical Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- ketamine, pharmacokinetics, bioavailability, analgesia, pain threshold, first-pass metabolism, intramuscular injection, oral administration, intravenous administration, two-compartment model, terminal half-life
- MeSH terms
- Administration, Oral, Adult, Analgesics, Biological Availability, Physical Exertion, Humans, Injections, Intramuscular, Injections, Intravenous, Ketamine, Kinetics, Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.